News

Innocoll, a biopharmaceutical company, has reported that the last patient has been dosed in the first of two ongoing US Phase III clinical trials sponsored by its wholly

According to OrSense, the NBM-200MP system offers for the first time a non-invasive, continuous and accurate measurement of oxygen saturation in states of hypovolemia, hypothermia and vasoconstriction or

The validity of the German patent is being challenged by Medela, Molnlycke Health Care, and Smith & Nephew. The decision is not final and KCI and Wake Forest

According to Flexible Stenting Solutions, this next-generation femoropopliteal stent and delivery system can significantly improve patient care in the high growth peripheral vascular segment. The fully connected flexible

Durect, a specialty pharmaceutical company, has announced positive results from a 74 patient Phase IIb clinical trial conducted by Endo Pharmaceuticals of Transdur-sufentanil, a seven day patch under

Shire, a specialty biopharmaceutical company, has decided to withdraw the European marketing authorization application for Daytrana for the treatment of attention deficit hyperactivity disorder. A request from European

The company reported net revenues of $11.15 million for the first quarter ended February 28, 2009, a 28% increase, compared to $8.69 million for the same period of

For the nine-month period ended January 31, 2009, the company reported a net loss of $1.02 million, or $0.03 per basic and diluted share, compared to a net

For the year ended December 31, 2008, the company reported a net loss of $14.37 million, or $1.09 per share, an increase of 31%, compared with a net